236 related articles for article (PubMed ID: 11270320)
21. Structure-activity relationships of dynorphin analogs substituted in positions 2 and 3.
Schlechtingen G; DeHaven RN; Daubert JD; Cassel J; Goodman M
Biopolymers; 2003; 71(1):71-6. PubMed ID: 12712501
[TBL] [Abstract][Full Text] [Related]
22. Alanine scan of the opioid peptide dynorphin B amide.
Joshi AA; Murray TF; Aldrich JV
Biopolymers; 2017 Sep; 108(5):. PubMed ID: 28464209
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 1. Conformational constraint in the "message" sequence.
Arttamangkul S; Murray TF; DeLander GE; Aldrich JV
J Med Chem; 1995 Jun; 38(13):2410-7. PubMed ID: 7608905
[TBL] [Abstract][Full Text] [Related]
24. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
25. Tetrapeptide derivatives of [D-Pen(2),D-Pen(5)]-enkephalin (DPDPE) lacking an N-terminal tyrosine residue are agonists at the mu-opioid receptor.
McFadyen IJ; Sobczyk-Kojiro K; Schaefer MJ; Ho JC; Omnaas JR; Mosberg HI; Traynor JR
J Pharmacol Exp Ther; 2000 Dec; 295(3):960-6. PubMed ID: 11082429
[TBL] [Abstract][Full Text] [Related]
26. ORL1 and opioid receptor preferences of nociceptin and dynorphin A analogues with Dmp substituted for N-terminal aromatic residues.
Sasaki Y; Kawano S; Kohara H; Watanabe H; Ambo A
Bioorg Med Chem; 2006 Apr; 14(7):2433-7. PubMed ID: 16321540
[TBL] [Abstract][Full Text] [Related]
27. Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.
Dolle RE; Michaut M; Martinez-Teipel B; Seida PR; Ajello CW; Muller AL; DeHaven RN; Carroll PJ
Bioorg Med Chem Lett; 2009 Jul; 19(13):3647-50. PubMed ID: 19464172
[TBL] [Abstract][Full Text] [Related]
28. Dynorphin A as a potential endogenous ligand for four members of the opioid receptor gene family.
Zhang S; Tong Y; Tian M; Dehaven RN; Cortesburgos L; Mansson E; Simonin F; Kieffer B; Yu L
J Pharmacol Exp Ther; 1998 Jul; 286(1):136-41. PubMed ID: 9655852
[TBL] [Abstract][Full Text] [Related]
29. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
[TBL] [Abstract][Full Text] [Related]
30. Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity.
Schiller PW; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Marsden BJ; Wilkes BC
J Med Chem; 1991 Oct; 34(10):3125-32. PubMed ID: 1656045
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and evaluation of opioid receptor-binding affinity of elaeocarpenine and its analogs.
Kurasaki H; Okamoto I; Morita N; Tamura O
Bioorg Med Chem Lett; 2010 Mar; 20(5):1601-3. PubMed ID: 20144865
[TBL] [Abstract][Full Text] [Related]
32. Opioid profiles of Cys2-containing enkephalin analogues.
Pencheva N; Milanov P; Vezenkov L; Pajpanova T; Naydenova E
Eur J Pharmacol; 2004 Sep; 498(1-3):249-56. PubMed ID: 15364002
[TBL] [Abstract][Full Text] [Related]
33. Interactions of dynorphin A and related peptides with cardiac ouabain binding sites.
Dumont M; Lemaire S
J Mol Cell Cardiol; 1996 Mar; 28(3):615-21. PubMed ID: 9011644
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological activity profile of new analogues of the cyclic opioid peptide H-Tyr-c[D-Cys-Gly-Phe(pNO2)-D-Cys]-NH2 containing (S)-alpha-hydroxymethylcysteine in place of cysteine.
Witkowska R; Chung NN; Schiller PW; Zabrocki J
J Pept Sci; 2005 Jun; 11(6):361-3. PubMed ID: 15635653
[TBL] [Abstract][Full Text] [Related]
35. [Aladan3]TIPP: a fluorescent delta-opioid antagonist with high delta-receptor binding affinity and delta selectivity.
Chen H; Chung NN; Lemieux C; Zelent B; Vanderkooi JM; Gryczynski I; Wilkes BC; Schiller PW
Biopolymers; 2005; 80(2-3):325-31. PubMed ID: 15614807
[TBL] [Abstract][Full Text] [Related]
36. Cyclic enkephalin analogs containing various para-substituted phenylalanine derivatives in place of Tyr1 are potent opioid agonists.
Weltrowska G; Lemieux C; Chung NN; Schiller PW
J Pept Res; 2005 Jan; 65(1):36-41. PubMed ID: 15686532
[TBL] [Abstract][Full Text] [Related]
37. Conformationally constrained formyl methionyl tripeptides: structure-function study of analogs containing alpha,beta-dehydrophenylalanine and dehydroleucine.
Bharadwaj A; Singh M; Bhandary K; Becker EL; Chauhan VS
Pept Res; 1993; 6(6):298-307. PubMed ID: 8292847
[TBL] [Abstract][Full Text] [Related]
38. Deletion of Ac-NMePhe(1) from [NMePhe(1) ]arodyn under acidic conditions, part 2: effects of substitutions on pharmacological activity.
Fang WJ; Bennett MA; Murray TF; Aldrich JV
Biopolymers; 2011; 96(1):103-10. PubMed ID: 20560148
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and evaluation of derivatives of leucine enkephalin as potential affinity labels for delta opioid receptors.
Choi H; Murray TF; Aldrich JV
Biopolymers; 2003; 71(5):552-7. PubMed ID: 14635095
[TBL] [Abstract][Full Text] [Related]
40. Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
Tóth G; Ioja E; Tömböly C; Ballet S; Tourwé D; Péter A; Martinek T; Chung NN; Schiller PW; Benyhe S; Borsodi A
J Med Chem; 2007 Jan; 50(2):328-33. PubMed ID: 17228874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
